Issue 2/1998
Content (13 Articles)
Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11}
J.D. Jonkman-de Vries, H. Rosing, H. Talsma, R.E.C. Henrar, J.J. Kettenes-van den Bosch, A. Bult, J.H. Beijnen
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units
Lillian L. Siu, Daniel D. Von Hoff, Ada Rephaeli, Elzbieta Izbicka, Cesario Cerna, Lionel Gomez, Eric K. Rowinsky, S. Gail Eckhardt
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs
Tomohiro Noda, Tomoyuki Watanabe, Akira Kohda, Shunji Hosokawa, Tadashi Suzuki
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate
Thomas H. Corbett, Patricia LoRusso, Lisa Demchick, Chiab Simpson, Susan Pugh, Kathryn White, Juiwanna Kushner, Lisa Polin, Jennifer Meyer, Jennifer Czarnecki, Lance Heilbrun, Jerome P. Horwitz, Janet L. Gross, Carl H. Behrens, Barbara A. Harrison, Ron J. McRipley, George Trainor
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study
Diana Lüftner, Bernd Flath, Costa Akrivakis, Hans-Günther Mergenthaler, Ute Ohnmacht, Michael Arning, Kurt Possinger
Phase I and pharmacokinetic study of intraperitoneal topotecan
Steven C. Plaxe, Randolph D. Christen, John O'Quigley, Patricia S. Braly, James L. Freddo, Edward McClay, Dennis Heath, Stephen B. Howell
Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia
S.A. Johnson, D. Catovsky, J.A. Child, A.C. Newland, D.W. Milligan, R. Janmohamed
A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck
Jonathan J. Beitler, Richard V. Smith, Hilda Haynes, Carl E. Silver, Astrid Quish, Tamar Kotz, Maria Serrano, Allan Brook, Scott Wadler
Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)
Frank L. Meyskens Jr., Joth Jacobson, Bichlien Nguyen, Geoffrey R. Weiss, David R. Gandara, John S. MacDonald
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma
Jaffer A. Ajani, Richard Pazdur, Pamela Dumas, Jackie Fairweather
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
Martin J. Edelman, Frederick J. Meyers, Tim Grennan, Jun Lauder, James Doroshow
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan
Yoshinori Ito, Noboru Horikoshi, Toru Watanabe, Yasutsuna Sasaki, Takeshi Tominaga, Tomohiko Okawa, Toshio Tabei, Yasunobu Kuraishi, Kazuo Tamura, Rikiya Abe, Masaki Kitajima, Susumu Yamaguchi, Tetsuro Kobayashi, Hiroki Koyama, Kunzo Orita, Shigemitsu Takashima, Yasuo Nomura, Makoto Ogawa
Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial
Robert S. Witte, Judith Manola, Patrick A. Burch, Timothy Kuzel, Eric L. Weinshel, Patrick J. Loehrer Sr.